Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Monitoring Kidney Cancer Patients After Surgery Using Tumor DNA in Blood

Studies blood tumor DNA changes over time in people having kidney cancer surgery.

Key facts

Who runs it
Jinling Hospital, China
Where
Nanjing, ChinaSee the site
Trial code
Registry title
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Status
Recruiting
People taking part
450 people, planned
Started
26 Dec 2022
Expected to end
Jun 2030
Type of study
Observational
Record updated
11 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed kidney cancer (renal cell carcinoma) who have had no treatment yet and agree to radical surgery.

Sex
Men and women can join.
Disease stage
Newly diagnosed renal cell carcinoma, not yet treated.
Earlier treatment
No treatment before. People who had any anti-cancer therapy before cannot join.

Main reasons for not taking part

  • Had other cancers
  • Had any anti-cancer therapy before
  • Known or suspected active autoimmune disease
  • Heart disease or symptoms that are not well controlled
  • Cannot give informed consent because of medical or psychiatric problems

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Newly diagnosed renal cell carcinoma
  • Without any treatment
  • Agree and accept radical surgical treatment
  • Signed written informed consent
  • ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1
  • Follow up protocol and related procedures

Who cannot take part

  • Had received any antitumor therapy before
  • Had other cancers
  • Known or suspected active autoimmune disease
  • Informed consent is not possible due to medical or psychiatric problems
  • Have clinical symptoms or diseases of the heart that are not well controlled
  • Patients judged by the investigators to be unsuitable for inclusion in this study

Where in China

  • Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaNanjing, ChinaContact: Le Qu, M.D.Taking people

About the trial

What the trial wants to find out

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Plain-language title
Monitoring Kidney Cancer Patients After Surgery Using Tumor DNA in BloodGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 December 2025